Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MPN Advances Day 2019 | CML data to watch for at ASH

Mhairi Copland • 15 Nov 2019
MPN Advances Day 2019
Chronic Myeloid Leukemia Leukemia Ponatinib
DESTINY MATCHPOINT

Speaking from the Myeloproliferative Neoplasms Advances Day 2019 in London, UK, Mhairi Copland, MB ChB, PhD, Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK, discusses the chronic myeloid leukemia (CML) research to watch out for at the American Society of Hematology (ASH) Annual Meeting and Exposition 2019.

More from Mhairi Copland

Co-targeting in CML: practical considerations & the potential of the bone marrow microenvironment
3:00
Co-targeting in CML: practical considerations & the potential of the bone marrow microenvironment
Mhairi Copland • 4 Sep 2025
How the management of CML is evolving & future directions
1:18
How the management of CML is evolving & future directions
Mhairi Copland • 5 Sep 2025
Current and future treatment strategies for blast-phase CML
3:05
Current and future treatment strategies for blast-phase CML
Mhairi Copland • 29 Sep 2022
The importance of improving treatment-free remission in patients with CML
1:36
The importance of improving treatment-free remission in patients with CML
Mhairi Copland • 29 Sep 2022

Related Videos

Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
AVC-201: a CAR-T using a switchable module in AML
13:39
AVC-201: a CAR-T using a switchable module in AML
Marion Subklewe • 19 Sep 2026
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
10:42
SENTI-202: a first-in-class logic-gated off-the-shelf CAR NK-cell therapy for R/R AML
Stephen Strickland • 19 Sep 2026
Managing FLT3-ITD mutant AML in remission
11:47
Managing FLT3-ITD mutant AML in remission
Eunice Wang • 19 Sep 2026
The content of VJHemOnc is intended for healthcare professionals